(Press-News.org) Four leading organizations in lifestyle medicine, obesity medicine, and nutrition—the American College of Lifestyle Medicine (ACLM), the American Society for Nutrition (ASN), the Obesity Medicine Association (OMA), and The Obesity Society (TOS)—have jointly released a clinical advisory titled “Nutritional Priorities to Support GLP-1 Therapy for Obesity.” Published across four peer-reviewed journals, this consensus-based guidance reflects an interdisciplinary collaboration to help clinicians support patients receiving GLP-1 receptor agonists for obesity care with evidence-based nutritional and behavioral strategies.
GLP-1 therapies, including both single and combination agents, have emerged as powerful tools in the management of obesity, demonstrating average placebo-adjusted weight reductions of 5–18% in clinical trials, along with improvements in metabolic, functional and cardiovascular outcomes. However, sustaining these benefits over time and maximizing patient outcomes require comprehensive care that integrates lifestyle intervention—particularly nutrition therapy—into the treatment plan.
“GLP-1s represent an important advancement in obesity care,” said lead author and advisory chair Dariush Mozaffarian, MD, DrPH, of Tufts University. “But these medications can present challenges, including gastrointestinal side effects, risk of micronutrient deficiencies, muscle and bone loss, poor long-term adherence with subsequent weight regain, and high costs; and, on their own, are not enough. Nutrition therapy and lifestyle support are essential components to address these challenges, help patients maximize and maintain health gains over time, and ensure we are using these drugs wisely, effectively, and without bankrupting the healthcare system.”
The advisory outlines eight key nutritional priorities to support patients on GLP-1 medications, emphasizing the importance of (1) patient-centered initiation of therapy, (2) careful baseline nutritional assessment, (3) management of gastrointestinal side effects, (4) personalized, nutrient-dense, minimally processed diets, (5) prevention of micronutrient deficiencies (6) adequate protein intake and strength training to preserve lean mass, (7) leveraging a good diet to maximize weight reduction, and (8) promoting other lifestyle changes around activity, sleep, mental stress, substance use, and social connections to maximize long-term success.
Recent evidence supports this integrative model. In studies evaluating combined pharmacologic and lifestyle interventions, patients receiving both GLP-1 therapy and structured nutrition guidance achieved greater weight loss, better adherence, and were more likely to sustain weight loss after discontinuing medication compared to those receiving pharmacotherapy alone (Wadden et al., 2021; Kushner et al., 2022).
Despite the known benefits, most individuals prescribed GLP-1s do not currently receive adequate nutritional counseling or behavioral support. This advisory seeks to fill that gap with practical, interdisciplinary guidance for implementation in clinical practice.
“GLP-1s are reshaping the landscape of obesity treatment, but it’s clear that medication alone is not a complete solution," stated John E. Courtney, PhD, Chief Executive Officer of the American Society for Nutrition. "This consensus-based guidance highlights the critical role of nutrition in supporting patients on GLP-1 therapy, with clear recommendations for health care providers to optimize outcomes, reduce risks, and fill urgent gaps in care through practical, evidence-informed nutrition strategies.”
While certain considerations—such as GI tolerance and micronutrient balance—are important for clinicians to address, the advisory emphasizes that a proactive lifestyle-based approach can mitigate risks and optimize outcomes. With obesity prevalence continuing to rise worldwide, the integration of nutrition therapy into GLP-1-based care offers a scalable strategy to extend the clinical and economic value of these therapies.
Clinicians are encouraged to use the advisory’s tools and frameworks to help patients translate nutrition guidance into sustainable behaviors, making lifestyle medicine an active ingredient in every “prescription” for obesity care.
The joint advisory is simultaneously published in the American Journal of Lifestyle Medicine (ACLM), The American Journal of Clinical Nutrition (ASN), Obesity Pillars® (OMA) and Obesity (TOS). Leading researchers will discuss the advisory and its implications during two sessions at NUTRITION 2025, the flagship annual meeting of the American Society for Nutrition to be held May 31–June 3 in Orlando, Florida:
Fatima Cody Stanford, MD, will speak on Nutrition Considerations with Long-term Use of GLP-1RA at 7:45 – 8:15 a.m. EDT on Saturday, May 31 during the Nutrition in Clinical Practice Course (presentation details).
Monica Agarwal, MD, will speak on Nutritional Priorities to Support GLP-1 Therapy for Weight Loss: A Joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society at 3:05 – 3:20 p.m. EDT on Sunday, June 1 during the Energy and Macronutrient Metabolism (EMM) GEM Forum, Meeting the Nutritional Needs of Patients on Anti-Obesity Medications: What’s New? (presentation details).
Reporters may register to attend NUTRITION 2025 or access selected recorded sessions online with a free press pass.
References:
Wadden TA, et al. Obesity (Silver Spring). 2021;29(S2):S1–S3.
Kushner RF, et al. JAMA Netw Open. 2022;5(10):e2239622
###
About the American Society for Nutrition (ASN)
ASN is the preeminent professional organization for nutrition research scientists and clinicians around the world. Founded in 1928, the Society brings together the top nutrition researchers, medical practitioners, policy makers and industry leaders to advance our knowledge and application of nutrition. ASN publishes four peer-reviewed journals and provides education and professional development opportunities to advance nutrition research, practice, and education. Since 2018, ASN has presented NUTRITION, the leading global annual meeting for nutrition professionals. For more information, visit www.nutrition.org.
About NUTRITION 2025
NUTRITION 2025 is the flagship meeting of the American Society for Nutrition and the premier educational event for nutritional professionals around the globe. NUTRITION brings together lab scientists, practicing clinicians, population health researchers, and community intervention investigators to identify solutions to today’s greatest nutrition challenges. Our audience also includes rising leaders in the field – undergraduate, graduate, and medical students. NUTRITION 2025 will be held May 31–June 3, 2025 in Orlando, Florida. https://nutrition.org/meeting #Nutrition2025
Find more news briefs from NUTRITION 2025 at: https://www.eurekalert.org/newsroom/nutrition2025.
END
In patients with diabetic foot ulcers that looked healed and met the current definition of a closed wound, closed ulcers with functionally defective skin that lost more body water were likely to re-open, according to a new National Institutes of Health (NIH) Diabetic Foot Consortium study, led by researchers at the University of Pittsburgh and published today in Diabetes Care.
The U.S. Food and Drug Administration (FDA) currently defines a closed wound as one where the surface is completely covered by new skin and ...
OAK BROOK, Ill. – Researchers have discovered that, compared to breast cancer that is symptom-detected, patients with breast cancer detected via routine screening mammography are more likely to have improved clinical outcomes, according to a study published today in Radiology: Imaging Cancer, a journal of the Radiological Society of North America (RSNA).
While it is commonly understood that early detection of breast cancer results in better patient outcomes, national cancer registries in the U.S. and Canada don’t track the method ...
The number of people living with a history of cancer in the United States is estimated at 18.6 million as of January 1, 2025 and projected to exceed 22 million by 2035, according to a new report, Cancer Treatment and Survivorship Statistics, 2025, led by the American Cancer Society (ACS). The study also found notable disparities in treatment for many common cancers, including lung and colorectal. The findings are published today in CA: A Cancer Journal for Clinicians, alongside its consumer-friendly companion, Fast Facts: Cancer Treatment and Survivorship, available on cancer.org.
“Behind every survivor of ...
A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led by researchers at Washington University School of Medicine in St. Louis.
The clinical trial evaluated the safety and efficacy of an innovative CAR-T cell immunotherapy that is specifically designed to attack cancerous T cells. Participants in the trial had been diagnosed with rare cancers — T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma — and had run out of treatment options after standard therapy proved ineffective for them. With the new immunotherapy, most of ...
A research team funded by the National Institutes of Health (NIH) has identified a diagnostic aid that has the potential to accurately predict the recurrence of diabetic foot ulcers that appear to be fully healed. By measuring the skin’s barrier function through a process known as trans-epidermal water loss, or TEWL, scientists were able to determine which wounds were more likely to reopen. TEWL measurements are a major factor in burn care, where deep layers of the skin are often damaged. The findings suggest that full restoration of skin ...
Complaint lines such as New York City’s 311 let people report quality-of-life problems in their building or neighborhood, from excessive noise to illegal parking. But resident-generated data typically suffer from reporting bias, with some neighborhoods and addresses calling attention to problems at lower rates than others.
A team of New York University researchers has developed an automated modeling tool to help the New York City government estimate 311 under-reporting by building, neighborhood, and subpopulation. In a new study, published today [May 30] in Annals of Applied Statistics, the researchers describe a method that, using machine learning, can estimate the potential ...
May 30, 2025 — A proposed classification system appears highly accurate in evaluating nasal deformities in infants with cleft lip and/or palate (CLP), reports a study in the May/June issue of The Journal of Craniofacial Surgery. The journal is published in the Lippincott portfolio by Wolters Kluwer.
"This new tool offers a reliable and practice tool for categorizing the severity of nasal deformities in CLP patients," comments lead author Martha Mejia, DDS, of Nicklaus Children's Health System, Miami. "With ongoing evaluation, it may promote more consistent diagnosis, individualized treatment planning, and standardized approaches ...
Background and objectives
This study investigates upper gastrointestinal tract (UGIT) involvement in patients with ulcerative colitis (UC), a condition traditionally considered limited to the colon. Although extra-colonic manifestations of UC are well recognized, UGIT issues have received less attention. This research aimed to document the clinical, endoscopic, and histopathological UGIT findings in adults with UC and assess their association with disease severity and extent.
Methods
This descriptive cross-sectional study was conducted at Ain Shams University over one year. A total of 78 UC patients underwent comprehensive clinical evaluations, including assessments ...
Approximately 8 to 12% of patients with colorectal cancer have BRAF mutations
Treatment with the triplet combination of drugs – encorafenib, cetuximab and chemotherapy – helped patients live longer and kept cancer from progressing
The Food and Drug Administration granted accelerated approval for this new combination in Dec. 2024
Median overall survival was 30.3 months with the triplet therapy, compared to 15.1 months with standard treatment
ABSTRACT: ...
Once organizations achieve their profitability and market performance targets, they often focus on additional goals. However, these goals do not always align and can sometimes conflict. For example, prioritizing shareholder returns may come at the expense of investments in social causes. This raises a critical question: How do companies decide where to allocate their surplus resources and which goals to prioritize?
A study published online in the Journal of Business Ethics on May 9, 2025, examines this question by turning the spotlight on the boardroom. A research team consisting of Professor Toru Yoshikawa from the School of Social Sciences, Waseda University, ...